Literature DB >> 11070021

The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN.

A Alcamí1, J A Symons, G L Smith.   

Abstract

Poxviruses encode a broad range of proteins that interfere with host immune functions, such as soluble versions of receptors for the cytokines tumor necrosis factor, interleukin-1 beta, gamma interferon (IFN-gamma), IFN-alpha/beta, and chemokines. These virus-encoded cytokine receptors have a profound effect on virus pathogenesis and enable the study of the role of cytokines in virus infections. The vaccinia virus (VV) Western Reserve gene B18R encodes a secreted protein with 3 immunoglobulin domains that functions as a soluble receptor for IFN-alpha/beta. We have found that after secretion B18R binds to both uninfected and infected cells. The B18R protein present at the cell surface maintains the properties of the soluble receptor, binding IFN-alpha/beta with high affinity and with broad species specificity, and protects cells from the antiviral state induced by IFN-alpha/beta. VV strain Wyeth expressed a truncated B18R protein lacking the C-terminal immunoglobulin domain. This protein binds IFN with lower affinity and retains its ability to bind to cells, indicating that the C-terminal region of B18R contributes to IFN binding. The replication of a VV B18R deletion mutant in tissue culture was restricted in the presence of IFN-alpha, whereas the wild-type virus replicated normally. Binding of soluble recombinant B18R to cells protected the cultures from IFN and allowed VV replication. This represents a novel strategy of virus immune evasion in which secreted IFN-alpha/beta receptors not only bind the soluble cytokine but also bind to uninfected cells and protect them from the antiviral effects of IFN-alpha/beta, maintaining the cells' susceptibility to virus infections. The adaptation of this soluble receptor to block IFN-alpha/beta activity locally will help VV to replicate in the host and spread in tissues. This emphasizes the importance of local effects of IFN-alpha/beta against virus infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11070021      PMCID: PMC113220          DOI: 10.1128/jvi.74.23.11230-11239.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

2.  Analysis of an interaction between the soluble vaccinia virus-coded type I interferon (IFN)-receptor and human IFN-alpha1 and IFN-alpha2.

Authors:  H Liptáková; E Kontseková; A Alcamí; G L Smith; P Kontsek
Journal:  Virology       Date:  1997-05-26       Impact factor: 3.616

3.  A specific surface antigen induced by poxvirus.

Authors:  Y Ueda; M Ito; I Tagaya
Journal:  Virology       Date:  1969-05       Impact factor: 3.616

4.  Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors.

Authors:  A Alcam; A Khanna; N L Paul; G L Smith
Journal:  J Gen Virol       Date:  1999-04       Impact factor: 3.891

Review 5.  Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections.

Authors:  C A Biron
Journal:  Semin Immunol       Date:  1998-10       Impact factor: 11.130

6.  A mechanism for the inhibition of fever by a virus.

Authors:  A Alcamí; G L Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling.

Authors:  O R Colamonici; P Domanski; S M Sweitzer; A Larner; R M Buller
Journal:  J Biol Chem       Date:  1995-07-07       Impact factor: 5.157

8.  Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity.

Authors:  A Alcamí; G L Smith
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

10.  Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins.

Authors:  K Mossman; C Upton; R M Buller; G McFadden
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

View more
  116 in total

Review 1.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

2.  Up-regulation of interferon-stimulated gene15 and its conjugates by tumor necrosis factor-α via type I interferon-dependent and -independent pathways.

Authors:  Kongthawat Chairatvit; Ariyaphong Wongnoppavich; Sirinthip Choonate
Journal:  Mol Cell Biochem       Date:  2012-06-23       Impact factor: 3.396

3.  Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Authors:  Liang-Chuan S Wang; Rachel C Lynn; Guanjun Cheng; Edward Alexander; Veena Kapoor; Edmund K Moon; Jing Sun; Zvi G Fridlender; Stuart N Isaacs; Stephen H Thorne; Steven M Albelda
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

4.  The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

Authors:  Shahram Salek-Ardakani; Rachel Flynn; Ramon Arens; Hideo Yagita; Geoffrey L Smith; Jannie Borst; Stephen P Schoenberger; Michael Croft
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

5.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

6.  Short peptide type I interferon mimetics: therapeutics for experimental allergic encephalomyelitis, melanoma, and viral infections.

Authors:  Chulbul M Ahmed; Howard M Johnson
Journal:  J Interferon Cytokine Res       Date:  2014-05-08       Impact factor: 2.607

7.  Glycosylation, disulfide bond formation, and the presence of a WSXWS-like motif in the orf virus GIF protein are critical for maintaining the integrity of Binding to ovine granulocyte-macrophage colony-stimulating factor and interleukin-2.

Authors:  C J McInnes; D Deane; D Haig; A Percival; J Thomson; A R Wood
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Genetic basis for adverse events after smallpox vaccination.

Authors:  David M Reif; Brett A McKinney; Alison A Motsinger; Stephen J Chanock; Kathryn M Edwards; Michael T Rock; Jason H Moore; James E Crowe
Journal:  J Infect Dis       Date:  2008-07-01       Impact factor: 5.226

9.  The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.

Authors:  Jonathan S Duke-Cohan; Kristin Wollenick; Elizabeth A Witten; Michael S Seaman; Lindsey R Baden; Raphael Dolin; Ellis L Reinherz
Journal:  Vaccine       Date:  2009-01-13       Impact factor: 3.641

10.  Human dendritic cells exhibit a pronounced type I IFN signature following Leishmania major infection that is required for IL-12 induction.

Authors:  Michelle A Favila; Nicholas S Geraci; Erliang Zeng; Brent Harker; David Condon; Rachel N Cotton; Asha Jayakumar; Vinita Tripathi; Mary Ann McDowell
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.